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Original Article
IntroductIon
Traditional	Chinese	medicine	 prescriptions	 (TCMPs)	 have	
been widely applied in treating diseases for thousands of years 
in China. Based on complex multicomponent composition, 
active	 components	 of	TCMP	play	 a	multilink,	multitarget,	
and	multilevel	 treating	 effect.[1,2] Compatibility of Chinese 
Materia	Medica	is	a	characteristic	and	advantage	in	TCMP.	
Like drug–drug interactions of the modern medicine, the 
TCMP	 contain	 two	 or	more	medicinal	 herbs	 to	 introduce	
new	 pharmacological	 effects	 through	 a	 synergistic	 action	
or	 antagonistic	 effect.[3] However, the synergistic action or 
antagonistic	effect	might	have	influence	on	ADME	(absorption,	
distribution, metabolism, and elimination) of some components 
in	 the	TCMP	 in vivo.[4]	Therefore,	 a	 specific	 authoritative	
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A	 rapid	 and	high	 selective	ultra‑performance	 liquid	 chromatography	 (UPLC)	with	 tandem	mass	 spectrometry	method	 for	 simultaneous	
determination	of	six	compounds	including	albiflorin,	paeoniflorin,	picroside	I,	picroside	II,	saikosaponin	A,	and	saikosaponin	D	in	rat	plasma	
was developed and validated using butyl p-hydroxybenzoate as an internal standard. One-step direct protein precipitation with acetonitrile was 
used	to	extract	the	compounds	from	the	rat	plasma	samples.	Chromatographic	separation	was	achieved	using	an	ACQUITY	UPLC	BEH	C18 
column (100 mm × 2.1 mm, 1.7 µm)	at	a	flow	rate	of	0.4	mL/min,	using	gradient	mode	containing	0.1%	formic	acid	in	water	and	acetonitrile	
were used as the Mobile phase A and B. Electrospray ionization in negative ion mode and multiple reaction monitoring were used to identify 
and quantify active components. Calibration curves showed good linearity (R2 > 0.9908) over a wide concentration range for all compounds. 
The intra- and interday precision (relative standard deviation) ranged 2.4%–7.0% and 2.6%–8.0%, respectively. The accuracy (relative error) 
was	from	−13.0%	to	13.2%	at	all	quality	control	levels.	The	recovery	ranged	from	81.1%	to	92.5%.	The	validated	method	was	successfully	
applied to pharmacokinetic study in rats after oral administration of Qing Gan‑Shu Yu‑Fang. The results show that one can draw a conclusion 
that these six active ingredients can be quickly absorbed and play a pharmacodynamic role rapidly in vivo.
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method should be established that provides recommendations 
for	pharmacokinetic	(PK)	studies	of	TCMP.
Qing Gan‑Shu Yu‑Fang (QGSYF)	 is	 a	 clinical	 experience	
formula which has been used to the treatment of chronic viral 
hepatitis that was summed up by the Chinese Medicine master 
Professor	Fujin	Duan	in	several	decades	of	Chinese	medicine	
clinical treatment. The compound prescription composed 
of Picrorhiza rhizome, Paeoniae radix alba, and Bupleuri 
radix (1:1:1,	 g/g/g).	The	 chemical	 constituents	 of	QGSYF	
mainly include iridoid glucosides (including picroside I and 
picroside	 II),	monoterpene	 glycosides	 (including	 albiflorin	
and paeoniflorin), and triterpenoid saponins (including 
saikosaponin A, and saikosaponin D). In consideration of 
constituents	in	individual	herb	from	QGSYF,	the	main	active	
ingredients of Picrorhiza rhizome are picroside I and picroside 
II. Recent studies have exhibited that picroside I and picroside 
II have protective,[5,6]	 anti‑inflammation,[7,8] antioxidant,[9,10]
potentiation of nerve growth factor action,[11] and anticancer[12]
activities.	Paeoniflorin	and	albiflorin	are	the	primarily	effective
ingredients in Paeoniae radix alba,	and	paeoniflorin	has	been
used as a target marker for the quality control (QC) of Paeoniae
radix alba	in	Chinese	Pharmacopoeia.	Pharmacological	studies




saponins, saikosaponin A, and saikosaponin D as the principal 
component have been observed have hepatoprotective
effects,[19] activation of antitumor effector cells,[20] and
anti‑inflammatory	activities.[21]
To	the	best	of	our	knowledge,	there	are	many	PK	reports	about	
TCMP,	 only	 determination	 of	 the	 active	 ingredients	 from	
the single herb in rat plasma.[22-24] However, there are rare 
literatures on pharmacokinetic studies of active ingredients 
in	 SGQYF.	Obviously,	 the	 study	 on	multiple	 activities	 of	
TCMP in vivo becomes very important in the development 
and clinical application of this potential new drug. In 
previous study, we have reported a high-performance liquid 
chromatography	coupled	with	photodiode	array	(HPLC‑PDA)	
method	for	simultaneous	quantification	of	picroside	I,	II	and	
albiflorin,	 paeoniflorin	 of	QGSYF	 particles	 and	 a	HPLC	
coupled with evaporative light scattering detector (ELSD) 
method	for	simultaneous	quantification	of	saikosaponin	A	and	
saikosaponin	D	of	QGSYF	particles	in	vitro.[24] Moreover, the 
six	ingredients	are	the	major	component	of	QGSYF,	which	to	
play a treatment role. Hence, it is urgent to establish a rapid 
and sensitive ultra-performance liquid chromatography with 
tandem	mass	 spectrometry	 (UPLC‑MS/MS)	method	and	 to	
perform	the	PK	research	of	the	six	active	constituents	from	
QGSYF	in vivo.	Unlike	conventional	HPLC,	UPLC	has	the	
advantages of a greater resolution, higher sensitivity, shorter 
running time, and less solvent consumption.[25] In addition, 
MS/MS technology could overcome the shortcoming that the 
absence of chromophore saikosaponin A and saikosaponin 
D hampers their detection usingan ultraviolet detector, so as 
to	 achieve	 the	 objective	 to	 simultaneously	 determining	 the	
six ingredients. The aim of the quantitative study in vitro is 
only	to	establish	an	accepted	standard	for	primarily	effective	
ingredients of herbs or prescriptions. However, to further 
improve dose regimen, understand herb–herb interaction 
mechanism	and	exert	maximal	therapeutic	efficacy	for	drugs	
which will need to establish a series of studies in vivo for 
QGSYF.	 PK	 studies	 are	 useful	 to	 explain	 and	 foresee	 the 
in vivo process of active ingredients after oral administration 
of	QGSYF	and	to	improve	dose	regimen	and	to	avoid	adverse	
effects.
In the present article, we developed and validated a rapid, 
efficient,	 and	 sensitive	 UPLC‑MS/MS	method	 for	 the	
simultaneous determination of albiflorin, paeoniflorin, 
picroside I, picroside II, saikosaponin A, and saikosaponin D 
in rat plasma. It was expected the results of this study could not 
only	facilitate	to	apprehend	the	action	mechanism	of	QGSYF	
but also help to make rational use of it.
experImental
Materials and reagents
The reference standards of picroside I and picroside II 
(purity >98%) were purchased from the Munster Biological 
Technology Co., Ltd. (Chengdu, China). The reference 
standard	 of	 albiflorin	 (purity	 >98%)	was	 purchased	 from	
Yifang	Biological	Technology	Co.,	 Ltd.	 (Tianjin,	China).	
The	 reference	 standard	of	 paeoniflorin	 and	 saikosaponin	A	
and saikosaponin D (purity >98%) was purchased from the 
National	Institutes	for	Food	and	Drug	Control	(Beijing,	China).	
The reference standard of butyl p-hydroxybenzoate (internal 
standard [IS]) (purity >98%) was purchased from the Guangfu 
Fine	Chemical	Research	 Institute	 (Tianjin,	China).	 Pieces	
prescription was collected from the Bozhou Traditional Chinese 





USA). Ultra-pure water was prepared from a Milli-Q water 
purification	system	(Bedford,	MA,	USA).	All	other	reagents	
were of analytical grade.
Instrumentation and analytical conditions
Chromatographic separation was achieved using an ACQUITY 
UPLC	system	(Waters	Corp.,	Milford,	MA,	USA)	comprised	
a binary pump with integrated degasser, autosampler 
with thermostat, and thermostatted column compartment. 
Chromatographic separation was achieved on an ACQUITY 
UPLC	BEH	C18 column (100 mm × 2.1 mm, 1.7 µm). 
A gradient elution with water (containing 0.1% formic 
acid) (A)-acetonitrile (B) was used. The flow rate was 
0.4 mL/min. The gradient program was as following: 
0–4.0 min, 90%–82% A, 4.0–4.5 min, 82%–70% A, 
4.5–6.0 min, 70%–67% A, 6.0–6.5 min, 67%–50% A, 
6.5–9.5 min, 50%–42% A, 9.5–10.0 min, 42%–90%, and 
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10.0–11.5 min, 90% A. All sample extracts were maintained 
in	the	autosampler	at	4°C	and	the	injection	volume	was	5	µL.
The	LC	system	was	coupled	with	an	API	4000	QTRAP	mass	
spectrometer system (Applied Biosystems/MDS SCIEX, USA) 




instrument control, data acquisition, and data analysis. All 
compounds were quantitatively determined by the multiple 
reaction monitoring (MRM) mode with the transitions of 
m/z	 479.3	→	121.0	 for	 albiflorin,	m/z	 479.3	→	121.2	 for	
paeoniflorin,	m/z	 491.0	→	147.0	 for	 picroside	 I,	 and	m/z 
511.0	→	 235.0	 for	 picroside	 II,	m/z	 779.8	→	 617.8	 for	
saikosaponin A, m/z	779.7	→	617.5	for	saikosaponin	D,	and	m/z 
193.0	→	91.9	for	IS.	The	structures	and	MS2 spectra of these 
compounds are shown in Figure 1. The mass spectrometric 
parameters were set as follows: ion spray voltage 4500 V; 
turbo spray temperature 550°C; nebulizer gas (gas 1), 55 psi; 
heater gas (gas 2), 55 psi; and curtain gas 20 psi; nitrogen 
was used in all cases. The declustering potential and collision 
energy are optimized for each compound and selected values 
are showed in Table 1.
Preparation of Qing Gan‑Shu Yu‑Fang extracts and 
determination of active compounds in the extracts
Powdered	Picrorhiza Rrhizome (150g), Paeoniae radix alba 
(150 g), and Bupleuri radix (150g) were mixed together 
(the three plant materials were mixed in a ratio of 1:1:1) 
and then were extracted three times with 2700 mL of 
ethanol–water	(70:30,	v/v)	refluxing	for	2	h,	respectively.	The	
extraction	solution	was	obtained	to	be	filtered	and	concentrated	
to 1 g/mL crude drug under reduced pressure. The administered 
dose of six compounds in the extract were quantitatively 
assessed	 by	HPLC‑ELSD	method	 and	 the	 contents	were	
20.34 mg/mL (picroside I), 31.14 mg/mL (picroside II), 
9.92 mg/mL (albiflorin), 14.47 mg/mL (paeoniflorin), 
5 .90 mg/mL (saikosaponin A),  and 0.99 mg/mL 
(saikosaponin D), respectively.
Preparation of stock solution, standard, and quality control 
samples
The	 stock	 solutions	 of	 albiflorin,	 paeoniflorin,	 picroside	 I,	
picroside II, IS, and saikosaponin A, and saikosaponin D 
were separately prepared by dissolving the precisely weighed 
reference compounds in methanol. All the stock solutions were 
stored at 4°C until use. Stock solutions of these compounds 






DP (V) CE (V)
Albiflorin 479.3 121.0 −80.42 −29.38
Paeoniflorin 479.3 121.2 −80.42 −29.38
Picroside	I 491.0 147.0 −109.90 −21.05
Picoside	II 511.0 235.0 −79.60 −35.86
Saikosaponin A 779.8 617.8 −175.03 −51.37
Saikosaponin D 779.7 617.5 −175.03 −51.37
IS 193.0 91.9 −81.74 −33.48
DP:	Declustering	potential,	CE:	Collision	energy,	IS:	Internal	standard
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were mixed and a series of standard working solutions were 
further prepared by dilution with methanol to provide seven 
standards of suitable desired concentration. Calibration samples 
were prepared by spiking 150µL rat blank biological matrix 
with 20 µL mixed working solutions. The calibration standards 
were prepared by spiking the working solution into blank rat 
plasma	at	concentrations	of	4.70–940.0	ng/mL	for	albiflorin,	
4.80–960.0	 ng/mL	 for	 paeoniflorin,	 5.10–1020	 ng/mL	 for	
picroside I, 0.98–490.0 ng/mL for picroside II, 0.55–220.0 ng/mL 
for saikosaponin A, 0.60–90.00 ng/mL for saikosaponin D, 
and 15.00 ng/mL for IS, respectively. The QC samples were 
extracted at high, medium, and low concentrations for each 
compound	(18.80,	94.00,	and	940.0	ng/mL	for	albiflorin;	19.20,	
96.00,	 and	960.0	ng/mL	 for	paeoniflorin;	20.40,	102.0,	 and	
1020 ng/mL for picroside I; 9.80, 49.00, and 490.00 ng/mL for 
picroside II; 11.00, 44.00, and 220.0 ng/mL for saikosaponin 
A; and 12.00, 24.00, and 120.00 ng/mL for saikosaponin D) 
in the same procedure with the standard calibration samples.
Plasma sample preparation
Plasma	samples	were	transferred	out	of	the	refrigerator	(−40°C)	
and thawed at room temperature. The thawed samples were 
extracted using a simple liquid–liquid extraction technique 
by direct protein precipitation with acetonitrile. To an aliquot, 
20.0 µL of the IS (butyl p-hydroxybenzoate, 15.00 ng/mL) and 
600 µl acetonitrile were added to 150 µl of the plasma sample 
were combined and vortex-mixed vigorously for 3 min. The 
mixture was centrifugation at 12000 rpm for 10 min at 4°, and 
700 µL of supernatant was transferred to a clean test tube and 
was completely evaporated to dryness under a gentle stream 
of	nitrogen	gas	at	40°C.	Finally,	the	residue	was	reconstituted	
in 100 µl of methanol/water (50:50, v/v), vortex-mixed for 






chromatograms at the retention times of blank plasma collected 
from	six	different	 rats,	plasma	spiked	with	compounds	and	
IS and plasma obtained after gavage of extract of the drug 
pair to investigate the potential interferences and to ensure 
no interference at the peak region of endogenous matrix 
compounds.
Calibration curve and lower limit of quantification
The linearity of calibration curve was assessed by analyzing 
seven concentration levels of standard plasma samples 
and constructed by plotting the peak area ratios (Y) of 
compounds to IS against the nominal concentration samples 
in plasma of compounds (X, ng/mL), using a 1/x2 weighted 
linear least squares regression model. The lower limit of 
quantification	 (LLOQ)	was	define	 as	 the	 lowest	 amount	of	
compounds in plasma samples that can be detected precisely 
with a level of acceptable accuracy (relative error [RE] ± 20%) 
and precision (relative standard deviation [RSD] < 20%) under 
a stated experimental condition. In addition, the signal-to-noise 
ratio(S/N)of the LLOQ sample considering should be at least 
five	times	the	signal	of	the	baseline	noise.
Precision and accuracy
Three concentration levels of QC samples (n = 5) by 
replicate analysis in each run to assess the intraday precision 
and accuracy (on 1 day) and interday precision and 
accuracy	 (between	 three	 different	 days)	 of	 the	 assay.	The	
precision and accuracy of analytical procedure were assessed 
as the RSD and RE of a series of measurements, respectively. 
The values of the precision (RSD%) and accuracy (RE%) were 
acceptable were all within ± 15% deviation from the nominal 
concentration.
Stability
Stability of the six compounds in rat plasma was evaluated by 
analyzing replicate QC samples (n = 5) of three levels under 
following storage conditions: short time stability (exposing QC 
samples at room temperature for 4 h which longer than the time 
of routine preparation samples), long time stability (keeping 
QC	samples	at	−20°C	for	2	weeks),	postpreparation	stability	
(placing QC samples in the autosampler at 4°C for 12 h), and 
freeze-thaw cycle stability (through three freezes-thaw cycles 
from	−20°C	to	room	temperature	on	consecutive	days).	Freshly	
calibration curve was prepared used to analyzing the stability 
of QC samples.
Extraction recovery and matrix effect
The extraction recovery of six compounds was evaluated by 
analyzing the ratio of the peak area for postextraction blank 
plasma-spiked compounds against preextraction blank plasma 
added compounds at three QC levels (low, medium, and 
high	concentration	levels).	The	matrix	effects	were	assayed	
by comparing the peak responses of compounds spiked into 
the pretreated blank rat plasma with those of corresponding 
concentration pure standard solutions, the IS was determined 
through a similar process method.
Animal
Healthy male Sprague-Dawley rats (300–350 g) were supplied 
by	the	Experimental	Animal	Center	of	Heilongjiang	University	
of Traditional Chinese Medicine. The rats were kept in an 
environmentally controlled room (25 ± 2°C, relative humidity 
50 ± 10%), with a natural light–dark cycle for 7 days before 
the experiment was carried. Before the drug administration, 
they were fasted for 12h and free access to water. All animal 
experiments were achieved according to the regulations of 
experimental animal administration approved by the State 
Commission	 of	 Science	 and	Technology	 of	 the	 People’s	
Republic of China.
Pharmacokinetic and statistical analysis
Six	 rats	were	orally	 administered	QGSYF	at	 a	 single	 dose	
which equivalent to 6 g/kg body weight of crude drug was 
used	 to	 investigate	 the	 PKs	 of	 compounds	 of	 drug	 pair	
extract. The rat blood samples about 300 µl were gathered 
from the suborbital vein into heparinized tubes before dosing 
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and 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24h after oral 
administration. And then, the samples were immediately 
centrifuged at 12000 rpm for 10 min, and the supernatants 
were	transferred	into	polypropylene	tubes	and	stored	at	−40°C	
until analysis. The daily calibration curves were constructed to 
calculate the concentration of the six compounds in rat plasma 
samples	at	different	time	points.	All	the	data	were	expressed	
as	mean	 ±	 SD.	The	 PKs	 parameters	 including	maximum	
plasma concentration (Cmax), the time to reach Cmax (Tmax), 
elimination of half-life time (T1/2), and area under the curve 
(AUC0-t and AUC0‑∞).
results
Mass and mobile conditions optimization
In our study, to get symmetric peak shapes, appropriate 
retention time, and optimized responses for the compounds. 
Methanol, acetonitrile, pure water, and 0.1% formic water were 
tested	as	potential	phases,	the	final	gradient	elution	phases	were	
chosen with acetonitrile and 0.1% formic water to achieve 
the optimal peak shapes, running time, and sensitivity. Butyl 
p-hydroxybenzoate as an IS was selected for its similarity 
retention time, ion mode, and stable-labeled structure with 
those compounds. In addition, the MRM mode was used 
to simultaneous determination of multiple components of 
QGSYF.	To	obtain	the	optimal	ionization	mode,	the	ESI	full	
scan mode was chosen, the ultimate results demonstrated that 
all compounds and IS were more suitable in negative ion mode 
which show stronger relative intensity than positive ion mode.
Method validation
Specificity
The typical chromatograms of blank rat plasma, blank plasma 
spiked with mixture of six compounds and IS, and the plasma 
samples	collected	after	administration	of	QGSYF	extract	are	
shown in Figure 2. Under the established chromatographic 
conditions, the endogenous and impurities interferences have not 
been discovered at the peak region of compounds and IS. The 
retention	time	of	albiflorin,	paeoniflorin,	picroside	I,	picroside	II,	
saikosaponin A, saikosaponin D, and IS was found to be about 
3.11, 3.67, 6.13, 5.58, 8.05, 8.56, and 8.55 min, respectively.
Linearity and lower limit of quantification
The typical calibration curves of six compounds all shared good 
linearity	with	satisfactory	correlation	coefficients	(R2 > 0.9908). 
The results for LLOQs of six compounds are appropriate for 
quantitative detection studies. In addition, the LLOQs for 
albiflorin,	paeoniflorin,	picroside	I,	picroside	II,	saikosaponin	
A, and saikosaponin D were 4.70, 4.80, 5.10, 0.98, 0.55, and 




One could draw conclusions that all the values for intra- and 
interday precision and accuracy of QC samples at three 
concentrations was within the accepted variable limits, the 
established method was overall precise and accurate. The 
intra- and interday precision were ranged from 2.4% to 7.0% 
and 2.6% to 8.0%, respectively, the accuracy was within 13.0% 
to 13.2%. The results were displayed in Table 3.
Stability
The stability assay results were summarized in Table 4. The 
results indicating that the six compounds in rat plasma samples 
were stable	under	different	store	conditions	for	4	h	at	room,	
2	weeks	at	−20°C,	 three	freeze‑thaw	cycles,	and	12	h	after	
pretreatment in the autosampler. The range of variation for 
concentrations was within 15% of the actual value.
Extraction recovery and matrix effect
As displayed in Table 5, the mean extraction recovery of 
compounds at three concentration levels in plasma samples 
was all between 81.1% and 92.5%, within acceptable range. 
The	matrix	effect	of	 six	 compounds	 ranged	 from	90.1%	 to	
101.7%, these data indicated that there was no obvious matrix 
effect	under	the	current	condition. Hence, further proof that 
the established method was stable and reliable.
Pharmacokinetic studies
The established method was successfully applied to 
simultaneous determination of the six compounds in rat blood 
plasma	 samples	 for	 PK	 study.	Drug	 and	Statistics	 (DAS)	
2.0	 software	 (Mathematical	 Pharmacology	 Professional	
Committee, Shanghai, China) was used to obtain correlation 
PK	parameters	and	are	present	in	Table 6. The mean plasma 
concentration‑time	profiles	of	six	compounds	are	illustrated	
in Figure 3.
The Tmax of picroside I and picroside II were 1.0 ± 0.5 h and 
1.2	±	0.7	h,	respectively.	Therefore,	it	is	difficult	to	accumulate 
in vivo for the two compounds with a short residence time and 
can be eliminated quickly. This is likely due to picroside I and 
Table 2: Calibration curves, linear range, lower limit of quantification for the six compounds
Analyte Regression equation Linear range (ng/ml) R2 LLOQ (ng/ml)
Albiflorin y=5.28×10−4X−1.16×10−2 4.70-940.0 0.9908 4.70
Paeoniflorin y=9.11×10−4X+4.76×10−3 4.80-960.0 0.9999 4.80
Picroside	I y=3.74×10-4X–3.00×10-3 5.10-1020 0.9974 5.10
Picoside	II y=5.89×10-3X–4.19×10-2 0.98-490.0 0.9979 0.98
Saikosaponin A y=2.05×10−3X−1.36×10−2 0.55-220.0 0.9968 0.55
Saikosaponin D y=2.23×10−3X−8.91×10−3 0.60-90.00 0.9972 0.60
LLOQ:	Lower	limit	of	quantification
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Figure 2: Representative multiple reaction monitoring chromatograms of albiflorin, paeoniflorin, picroside I, picroside II, saikosaponin A, saikosaponin 
D, and internal standard in rat plasma. (a) Blank plasma, (b) blank plasma spiked with six compounds at lower limit of quantification and internal 
standard, (c) plasma from a rat 1 h after oral administration of Qing Gan‑Shu Yu‑Fang
cba
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picroside	II	are	iridoid	glycosides,	previous	reports	about	PKs	
suggest that iridoid glycosides show a less bioavailability due 
to their extensive metabolism through various pathways.[26,27]
Paeoniflorin	 and	 albiflorin	 are	 two	major	monoterpene	
glycosides of Paeoniae radix alba, which are also the most 
important	active	ingredients,	play	treating	effect	of	this	herb.	
Inthe previous report, these two compounds show similar 
Tmax and similar characteristics and tendencies in plasma 
drug–time	curve	profiles	 after	oral	 administration	of	 signal	
herbal. This could be because of the similar structure of these 
two compounds.[23]	However,	 two	 compounds	 are	 different	
Tmax (0.9 ± 0.6h and 0.7 ± 0.3h) in plasma drug–time curve 
profiles	after	oral	administration	of	QGSYF,	even	longer	than	
in a single herbal.
Saikosaponin	A	and	saikosaponin	D	are	two	major	triterpenoid	
saponins of Bupleuri radix. Compared with another four 
triterpenoid saponins, saikosaponins A and Dhave lower 
content in this compound prescription. Recent reports suggest 
that	 it	 is	 difficult	 to	 enter	 the	 body	 through	 the	 intestinal	
membranes for saponins.[28] Moreover, the structure of the 
two saikosaponins was unstable and easily convertible in the 
gastrointestinal tract. Therefore, the two compounds showed 
a lower concentration in rat plasma samples. However, the 
current study indicates that saikosaponin A and saikosaponin D 
were quickly absorbed with a Tmax	about	30	min.	Furthermore,	
saikosaponin A and saikosaponin D were usually used as marker 
for the QC of Bupleuri radix.[29] However, the T1/2 values of 
saikosaponin D (14.5 ± 7.0h) are a little longer than previous 
studies including oral administration of monomer, bupleurum 
extract, and prescription.[24,30] A probable explanation was 
that the other unknown components of the other two herbals 
may inhibit the elimination of saikosaponin D in rats. This 
hypothesis will be one of the directions of our future research.
dIscussIon
The experimental results showed that the variation in 
bioavailability	 of	 paeoniflorin	 and	 albiflorin	 from	different	
preparations attributed to the presence of some other 
compounds	 in	 QGSYF	which	 are	 likely	 to	 inhibit	 the	
metabolism of paeoniflorin and albiflorin. The unknown 
compounds most likely from the other two herbals. These also 
results suggested that herb–herb interactions occurred in vivo 
after	 oral	 administration	 of	QGSYF	 in	 rats.	Thus,	 further	
mechanistic study has to be conducted in future to understand 
the	actual	reason	for	low	bioavailability	of	paeoniflorin	and	
albiflorin	in	QGSYF.
In short, one can draw a conclusion that these six 
active ingredients can be quickly absorbed and play a 




a	flesh,	 rapid,	 sensitive,	 simple	UPLC‑MS/MS	method	was	
performed which used for determination of six kinds of 
Table 3: Summary of accuracy and precision of the six 
compounds in rat plasma (n=5)
Analytes Concentration (ng/mL) RSD (%) Accuracy 
(RE, %)Spiked Measured Intra‑day Inter‑day
Albiflorin 18.80 20.43±0.86 4.2 6.4 8.7
94.00 102.3±2.45 2.4 5.5 8.8
940.0 973.9±39.7 4.1 4.2 3.6
Paeoniflorin 19.20 19.54±0.88 4.5 6.1 1.7
96.00 108.0±4.08 3.8 4.9 12.5
960.0 942.8±30.3 3.2 4.0 −1.8
Picroside	I 20.40 20.64±0.99 4.8 7.9 1.2
102.0 103.2±5.05 4.9 6.9 1.1
1020 1046.4±37.3 3.6 2.6 2.6
Picoside	II 9.80 8.61±0.50 5.8 7.4 −12.1
49.00 55.49±2.0 3.5 4.1 13.2
490.0 532.8±21.0 3.9 4.2 8.7
Saikosaponin 
A
11.00 9.66±0.47 4.8 7.6 −12.3
44.00 46.84±1.16 2.5 5.0 6.5
220.0 224.4±7.00 3.1 5.8 2.0
Saikosaponin 
D
12.00 10.44±0.73 7.0 8.0 −13.0
24.00 22.85±0.64 2.8 7.4 −4.8
120.0 130.59±5.92 4.5 5.0 8.8
RSD: Relative standard deviation, RE: Relative error
Figure 3: Mean plasma concentration time profiles of six compounds in rat plasma after oral administration of Qing Gan‑Shu Yu‑Fang (n = 6)
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compound	in	rat	plasma	after	oral	give	QGSYF.	Drawing	out	the	
concentration–time curves and calculating the corresponding 
PK	parameters	of	six	compound,	can	foster	better	understanding	
of	 the	 efficacy	 of	QGSYF,	 and	 can	 facilitate	 further	 to	
understand the herb–herb interaction and provide the theoretical 
basis and guidance for clinical application, the development 
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Short‑term Postpreparative Freeze‑thaw Long‑term
Albiflorin 18.80 4.8 6.2 9.1 10.8
94.00 6.6 9.8 6.7 9.5
940.0 3.2 4.0 5.2 7.2
Paeoniflorin 19.20 4.3 6.7 8.5 10.4
96.00 4.0 3.7 7.2 9.9
960.0 4.6 3.1 8.1 11.6
Picroside	I 20.40 5.1 5.8 7.1 10.9
102.0 2.9 6.8 5.0 8.1
1020 2.9 4.7 5.3 7.7
Picoside	II 9.80 4.4 4.4 4.2 7.6
49.00 3.6 5.0 5.9 6.6
490.0 2.7 2.8 4.3 5.0
Saikosaponin A 11.00 4.5 3.3 6.3 11.1
44.00 3.2 5.7 5.1 6.3
220.0 3.1 3.4 3.5 4.2
Saikosaponin D 12.00 3.3 5.8 6.0 7.1
24.00 5.6 5.5 6.4 6.8
120.0 4.6 3.7 4.9 5.6
Table 5: Stability data for compounds in rat plasma under different storage conditions (n=5)
Analytes Concentration (ng/ml) Recovery (%, mean±SD) RSD (%) Matrix effect (%, mean±SD) RSD (%)
Albiflorin 18.80 81.1±6.8 8.3 92.0±7.0 7.6
94.00 84.6±3.7 4.4 101.7±5.8 5.7
940.0 87.8±0.7 0.8 96.2±3.2 3.3
Paeoniflorin 19.20 84.0±8.3 9.8 90.1±1.5 1.7
96.00 86.6±2.1 2.4 92.3±7.1 7.7
960.0 88.6±1.9 2.1 94.8±2.8 3.0
Picroside	I 20.40 81.8±7.2 8.8 91.9±8.0 8.7
102.0 86.8±2.8 3.2 92.6±3.4 3.6
1020 87.9±1.7 2.0 98.6±7.1 7.2
Picoside	II 9.80 83.5±9.3 11.2 95.7±8.8 9.2
49.00 89.3±6.3. 7.0 90.8±3.0 3.4
490.0 92.5±5.3 5.8 97.0±3.4 3.5
Saikosaponin A 11.00 81.3±4.2 5.2 93.3±4.2 4.5
44.00 83.4±3.9 4.6 94.8±5.7 6.0
220.0 85.5±2.6 3.1 97.6±3.9 4.0
Saikosaponin D 12.00 80.8±8.0 10.0 90.5±7.9 8.8
24.00 91.5±5.6 6.1 92.1±2.6 2.8
120.0 90.1±2.4 2.7 93.9±2.3 2.5
RSD: Relative standard deviation, SD: Standard deviation
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Table 6: Pharmacokinetic parameters after oral administration of Qing Gan‑Shu Yu‑Fang (n=6)
Analyte Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0 ‑ t (ng/ml) AUC0‑∞ (ng/ml)
Albiflorin 318.6±33.7 0.7±0.3 10.0±0.9 3393.3±451.2 5279.6±1454.6
Paeoniflorin 525.8±66.3 0.9±0.6 11.1±4.2 6216.2±955.1 7997.7±1591.7
Picroside	I 91.3±14.1 1.0±0.5 14.5±0.1 878.6±76.8 1325.1±231.9
Picoside	II 232.5±40.6 1.2±0.7 11.0±2.8 2442.2±206.7 2934.7±286.1
Saikosaponin A 44.2±7.7 0.5±0.3 11.5±3.7 474.7±42.7 781.9±53.5
Saikosaponin D 9.7±1.5 0.5±0.3 14.5±7.0 115.3±28.8 340.0±195.5
AUC: Area under the curve
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